Associations of Cardiometabolic Multimorbidity With All-Cause and Coronary Heart Disease Mortality Among Black Adults in the Jackson Heart Study.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
entrez:
25
10
2022
pubmed:
26
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
A combination of diabetes, coronary heart disease (CHD), and stroke has multiplicative all-cause mortality risk compared with any individual morbidity in White populations, but there is a lack of studies in Black populations in the US. To examine the association of cardiometabolic multimorbidity (diabetes, stroke, and CHD) individually and collectively with all-cause and CHD mortality. This cohort study included Black adults in the Jackson Heart Study followed over a median of 15 years. Baseline examinations were performed between 2000 and 2004, with follow-up on all-cause and CHD mortality through May 31, 2018. Participants were categorized into mutually exclusive groups at baseline: (1) free of cardiometabolic morbidity, (2) diabetes, (3) CHD, (4) stroke, (5) diabetes and stroke, (6) CHD and stroke, (7) diabetes and CHD, and (8) diabetes, stroke, and CHD. Data were analyzed from 2019 to 2021. Cardiometabolic disease alone or in combination. The main outcomes were all-cause mortality and CHD mortality. Cox models estimated hazard ratios (HRs) with 95% CIs adjusted for sociodemographic and cardiovascular risk factors. Among 5064 participants (mean [SD] age, 55.4 [12.8] years; 3200 [63%] women) in the Jackson Heart Study, 897 (18%) had diabetes, 192 (4%) had CHD, and 104 (2%) had a history of stroke. Among participants with cardiometabolic morbidities, the crude all-cause mortality rates were lowest for diabetes alone (24.4 deaths per 1000 person-years) and highest for diabetes, CHD, and stroke combined (84.1 deaths per 1000 person-years). For people with only 1 cardiometabolic morbidity, risk for all-cause mortality was highest for people with stroke (HR, 1.74; 95% CI, 1.24-2.42), followed by CHD (HR, 1.59 (95% CI, 1.22-2.08) and diabetes (HR, 1.50; 95% CI, 1.22-1.85), compared with no cardiometabolic morbidities. There were also increased risks of mortality with combinations of diabetes and stroke (HR, 1.71; 95% CI, 1.09-2.68), CHD and stroke (HR, 2.23; 95% CI, 1.35-3.69), and diabetes and CHD (HR, 2.28; 95% CI, 1.65-3.15). The combination of diabetes, stroke, and CHD was associated with the highest all-cause mortality (HR, 3.68; 95% CI, 1.96-6.93). Findings were similar for CHD mortality, but with a larger magnitude of association (eg, diabetes, stroke, and CHD: HR, 13.52; 95% CI, 3.38-54.12). In this cohort study, an increasing number of cardiometabolic multimorbidities was associated with a multiplicative increase in risk of all-cause mortality among Black adults, with a greater magnitude of association for CHD mortality.
Identifiants
pubmed: 36282500
pii: 2797624
doi: 10.1001/jamanetworkopen.2022.38361
pmc: PMC9597394
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2238361Références
Circulation. 2012 Jun 19;125(24):2975-84
pubmed: 22619283
JAMA. 2002 May 15;287(19):2519-27
pubmed: 12020332
JAMA. 2016 Nov 8;316(18):1869-1870
pubmed: 27656867
Circulation. 2022 Mar;145(9):e722-e759
pubmed: 35000404
Circulation. 2022 Jul 19;146(3):175-190
pubmed: 35861762
JACC Heart Fail. 2017 Sep;5(9):642-651
pubmed: 28822744
Ethn Dis. 2005 Autumn;15(4 Suppl 6):S6-4-17
pubmed: 16320381
JAMA. 2012 Nov 7;308(17):1768-74
pubmed: 23117777
Ann Pharmacother. 2005 Sep;39(9):1489-501
pubmed: 16076917
J Gen Intern Med. 2019 Aug;34(8):1376-1378
pubmed: 30887434
Ethn Dis. 2007 Winter;17(1):143-52
pubmed: 17274224
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1205-1215
pubmed: 35026013
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
Am Heart J. 2022 May;247:1-14
pubmed: 35065922
N Engl J Med. 2011 Oct 20;365(16):1509-19
pubmed: 22010917
Curr Opin Cardiol. 2021 Sep 1;36(5):572-579
pubmed: 34397464
Am Heart J. 2010 Oct;160(4):744-51
pubmed: 20934570
Diabetologia. 2016 Sep;59(9):1893-903
pubmed: 27272340
Circulation. 2017 Nov 21;136(21):e393-e423
pubmed: 29061565
Public Health Rep. 2003 Jul-Aug;118(4):287-92
pubmed: 12815075
Curr Epidemiol Rep. 2022;9(3):212-221
pubmed: 36003088
Am J Med Sci. 2015 May;349(5):379-84
pubmed: 25806862
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
PLoS One. 2020 Sep 1;15(9):e0238374
pubmed: 32870944
Diabetologia. 2019 Mar;62(3):426-437
pubmed: 30643923
J Clin Endocrinol Metab. 2016 Apr;101(4):1770-8
pubmed: 26908112
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Am J Prev Cardiol. 2022 Jan 13;9:100315
pubmed: 35146467
Circulation. 2020 Dec 15;142(24):e454-e468
pubmed: 33170755
J Am Coll Cardiol. 2021 Dec 14;78(24):2471-2482
pubmed: 34886969
Curr Diab Rep. 2013 Dec;13(6):814-23
pubmed: 24037313
JAMA. 2021 Oct 5;326(13):1286-1298
pubmed: 34609450
Circulation. 2012 Jul 3;126(1):50-9
pubmed: 22693351
JAMA. 2015 Jul 7;314(1):52-60
pubmed: 26151266
Circ Res. 2022 Mar 4;130(5):782-799
pubmed: 35239404
Ethn Dis. 2005 Autumn;15(4 Suppl 6):S6-62-70
pubmed: 16317987
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Diabetes Res Clin Pract. 2021 Mar;173:108652
pubmed: 33422585
Am J Med Sci. 2004 Sep;328(3):131-44
pubmed: 15367870
Diabetes Care. 2003 Aug;26(8):2392-9
pubmed: 12882868